2seventy bio, Inc. (NASDAQ: TSVT) AI-Powered Stock Analysis
See how 2seventy bio, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
TSVT●NASDAQ
HealthcareBiotechnology
$5.00
$0.00(0.00%)
U.S. Market opens in 13h 45m
2seventy bio, Inc. (NASDAQ: TSVT) AI-Powered Stock Analysis
See how 2seventy bio, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer2seventy bio, Inc. (NASDAQ: TSVT) Stock Overall Grade
2seventy bio, Inc.'s grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to 2seventy bio, Inc.'s overall NASDAQ stock rating.
Forecast
C+Score
52/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
CScore
48/100Sector Comparison
BScore
65/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
C+Score
50/1002seventy bio, Inc. (NASDAQ: TSVT) AI-Powered Stock Analysis
On the NASDAQ, TSVT demonstrates Normal performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (48/100, C) and Sector Comparison (65/100, B) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests Moderate divergence in outlook.(NASDAQ: TSVT) Component Analysis Explained
Understand the key factors behind each 2seventy bio, Inc. (NASDAQ: TSVT) stock grade, including financials, comparisons, and forecasts.